Physic Ventures and Chrysalis Ventures Join Health Evolution Partners Innovation...
* Reuters is not responsible for the content in this press release.
Physic Ventures and Chrysalis Ventures Join Health Evolution Partners Innovation Network
Venture Firms Add Sector and Geographic Diversification
SAN FRANCISCO--(Business Wire)--
Health Evolution Partners, a manager of health care investment
funds, today announced the addition of Physic Ventures and Chrysalis
Ventures to the Health Evolution Partners Innovation Network (HEPIN).
The two new firms join existing fund partners, the Psilos Group and
Cardinal Partners.
HEPIN is a $200 million investment vehicle that invests in and
supports the companies that will pioneer a more efficient, higher
quality and consumer-focused health care system. HEPIN has developed a
hybrid strategy to achieve this goal - it invests in and works closely
with other funds with aligned missions, and also invests directly in
leading companies.
"Physic and Chrysalis have unique strategies and deep experience,"
said David J. Brailer, MD, PhD, Chairman of Health Evolution Partners.
"These firms extend our ability to invest in and support companies
that can transform health care and benefit from this change."
Physic has developed a unique focus and successful track record in
consumer driven health care by identifying companies that empower
consumers toward healthier lifestyles. Chrysalis' geographic focus in
the Midwest and South has enabled them to identify unique health
investment opportunities in these "under-ventured" regions of the
country.
"We are pleased to join with HEPIN and its respected management
and advisory team to further leverage our own expertise in building
companies with breakthrough ideas that are shaping the future of
health care, and particularly the role of consumers in managing their
own health and well-being," said William Rosenzweig, Managing Director
of Physic Ventures.
"This is a great match for us," said David Jones Jr., Chairman and
Managing Director Chrysalis Ventures. "There are brilliant,
transformative investment opportunities in our part of the country -
too often overlooked by venture capital firms focused on the coasts.
There really are no geographic boundaries in the search for ideas that
can revolutionize health care delivery."
"We look forward to working with the exceptional management teams
from these funds to bring breakthrough solutions from concept to
widespread national use," said Roy Ziegler, director of HEPIN.
Health Evolution Partners is a manager of health care investment
funds founded in 2007. Health Evolution Partners invests across the
health care industry, from early stage to buyouts and from services to
technologies. It is seeking companies that can lead and become
valuable in the new era of value-based, cost-effective and
consumer-driven health care. To learn more about Health Evolution
Partners, visit www.healthevolutionpartners.com.
Physic Ventures (www.physicventures.com), the first venture
capital firm dedicated to investing in consumer-driven health and
sustainable living, provides capital and support to entrepreneurs
focused on building exceptional science-based, consumer-directed
health and sustainable living companies. The firm's strategy is to
capitalize on major economic, social and political trends shaping the
landscape of personal and planetary health, including the rapid
migration toward a consumer-driven, prevention-oriented "self-care"
paradigm. Physic Ventures is based in San Francisco, CA.
Chrysalis Ventures (www.chrysalisventures.com), founded in 1993,
is a leading source of equity capital for young growth companies in
the Midwest and South. Chrysalis invests primarily in early-stage and
expansion-stage companies in healthcare services and technology, media
and communications, and business services. Based in Louisville,
Kentucky, Chrysalis has $375 million under management and has made
investments in over 55 companies.
Health Evolution Partners
Daniel Danzig, 925-254-6078
danzigpr@comcast.net
Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters